Disappointing trial results for Aerie Pharmaceuticals

Aerie Pharmaceuticals (Nasdaq: AERI) reported disappointing results from a Phase 3 registration trial for Rhopressa sending the stock price plummeting $21.42 to $13.97.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.